Variables Affecting Reconstitution Time of Dry Powder for Injection - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Variables Affecting Reconstitution Time of Dry Powder for Injection
The authors describe the factors affecting reconstitution time of dry powder for injection and classifies them as intrinsic and extrinsic parameters.


Pharmaceutical Technology


Within a particular method, reconstitution time is further dependent on several variables, including shaking frequency, height of stroke, inclination of the shaking axis, and the dimensions of the mockups. Thiermann et al. studied the reconstitution of HI 6 dichloride, a broad-spectrum cholinesterase reactivator, and observed that horizontal shaking reduced the frequency required for reconstitution (57). Shaking intensities may vary significantly among patients, healthy subjects, doctors, and nurses resulting in differences in reconstitution time (57). Freeze-dried or lyophilized protein drugs need unique reconstitution procedures to avoid excessive stress that might lead to foaming. Foaming causes physical instability of proteins such as denaturation, surface adsorption, aggregation, and precipitation, which might evoke undesired immune response in a patient. It is, therefore, recommended to reconstitute these drugs by either rolling them between palms or swirling thrm despite higher reconstitution times observed with these methods (58).

Storage conditions and storage time. A change in reconstitution time may be observed during storage of a PI. Common reasons include cohesion, crystal growth, and/or moisture sorption, which promote lump formation. Cohesional forces increase with reduced distance between the particles and become prominent in the powder cake, which is usually a result of vibrations experienced by the product during transit or storage. Stresses during storage might induce crystal-form transformations and ultimately alter the reconstitution time (59).

Treatment of glass vial. Glass vials are sometimes coated internally with a silicone fluid to produce a hydrophobic surface. This operation is usually performed to avoid sticking or adherence of drug to the glass vial, thereby ensuring better reconstitutability (60). However, use of organic cosolvents as diluent must be avoided with siliconized glass vials or stoppers because organic cosolvents can solubilize or extract silicone oil from the package component. The extracted silicone oil can impede the wetting of the affected portions of the cake, resulting in incomplete reconstitution (48).

Headspace of glass vial. PIs are considered small-volume parenterals and therefore packaged mostly in glass vials of volumes not more than 100 mL. The amount of headspace available determines the volume available for agitation of the product. A decrease in reconstitution time of dry-fill cyclophosphamide was observed by increasing the headspace of glass vials, which obviated the need of an expensive freeze drying process for improving the reconstitution time (61).

Temperature of diluent. The temperature of the diluent influences the reconstitution time. A significant reduction in reconstitution time was observed using diluent prewarmed to 41 C for dantrolene (62). Although a warmed diluent would speed up the reconstitution of almost any powdered substance, it might adversely affect the drug stability, which may necessitate the evaluation of the effect of temperature by conducting appropriate stability studies (62). Reconstitution of lyophilized amifostine powder (500 mg) with 2.9 mL sodium chloride solution or sterile water for injection at 20–25 C resulted in complete dissolution within minutes. Reconstitution with smaller volumes (2.0 or 2.5 mL), although feasible, required more time and/or a warmer temperature (63). Dissolution of amifostine for subcutaneous injection was thus proved to be volume and temperature dependent (63). Mitchell et al. showed that dantrolene solubility increases linearly with increasing temperature between 20 and 40 C (64). However, a temperature higher than 40 C is not recommended because it could cause red blood cell lysis and local tissue burns (64, 65).

Conclusion

Reconstitution, a pharmaceutical prerequisite for powder for injection, has direct implications on patient safety, making it a critical parameter to evaluate powder for injection formulations. Numerous intrinsic and extrinsic parameters affect the time and reproducibility of reconstitution of powders. Identification and control of these parameters during product development and quality control can reduce batch-to-batch variability in reconstitution time and provide confidence among the end users, thereby making the powder for injection formulation an attractive and safe alternative for moisture-sensitive drugs. A short and reproducible reconstitution time will also save the precious time and labor of caregivers while dealing in emergency situations, ensuring a more effective critical care during compromised clinical situations.

Pradip Hiwale, Aeshna Amin, and Lokesh Kumar are students and Arvind K. Bansal, PhD,* is an associate professor in the Department of Pharmaceutical Technology (Formulations) at the National Institute of Pharmaceutical Education and Research, Sector 67, Phase X, SAS Nagar, Punjab 160 062, India, tel. 91 172 2214682-87, fax 91 172 2214692,

*To whom all correspondence should be addressed.

Submitted: June 27, 2007. Accepted: Aug. 2, 2007.




What would you do differently? Email your thoughts about this paper to
and we may post them to the site.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here